- Title
- Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry
- Creators - without role
- Antonio Vitale - University of SienaValeria Caggiano - University of SienaMaria Cristina Maggio - University of PalermoGiuseppe Lopalco - University of Bari Aldo MoroGiacomo Emmi - University of FlorenceJurgen Sota - University of SienaFrancesco La Torre - Ospedale Pediatrico Giovanni XXIIIPiero Ruscitti - University of L'AquilaElena Bartoloni - University of PerugiaGiovanni Conti - Azienda Ospedaliera Universitaria Policlinico "G. Martino"Claudia Fabiani - University of SienaIrene Mattioli - University of FlorenceCarla Gaggiano - University of SienaFabio Cardinale - Ospedale Pediatrico Giovanni XXIIILorenzo Dagna - Vita-Salute San Raffaele UniversityCorrado Campochiaro - IRCCS Ospedale San RaffaeleRoberto Giacomelli - Università Campus Bio-MedicoAlberto Balistreri - University of SienaKaterina Laskari - National and Kapodistrian University of AthensAbdurrahman Tufan - Gazi UniversityGaafar Ragab - Cairo UniversityIbrahim A. Almaghlouth - King Saud UniversityEwa Więsik-Szewczyk - Central Clinical HospitalRosa Maria Pereira - Hospital das Clínicas da Faculdade de Medicina da Universidade de São PauloBruno Frediani - University of SienaFlorenzo Iannone - University of Bari Aldo MoroPetros P. Sfikakis - National and Kapodistrian University of AthensLuca Cantarini - University of Siena
- Publication Details
- Frontiers in medicine, Vol.9, pp.1071732-1071732
- Publisher
- Frontiers Media S.A
- Identifiers
- 9951155108331
- Academic Unit
- King Saud University
- Language
- English
- Resource Type
- Journal article
Journal article
Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry
Frontiers in medicine, Vol.9, pp.1071732-1071732
22/12/2022
PMID: 36619631
Metrics
1 Record Views